BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1063-78. [DOI: 10.1080/17425255.2020.1817380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Lou BX, Oks M. Insomnia: Pharmacologic Treatment. Clin Geriatr Med 2021;37:401-15. [PMID: 34210446 DOI: 10.1016/j.cger.2021.04.003] [Reference Citation Analysis]
2 Mehr JB, Mitchison D, Bowrey HE, James MH. Sleep dysregulation in binge eating disorder and "food addiction": the orexin (hypocretin) system as a potential neurobiological link. Neuropsychopharmacology 2021. [PMID: 34145404 DOI: 10.1038/s41386-021-01052-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Subramanian S, Ravichandran M. Orexin receptors: Targets and applications. Fundam Clin Pharmacol 2021. [PMID: 34464995 DOI: 10.1111/fcp.12723] [Reference Citation Analysis]
4 [DOI: 10.1101/2021.02.20.432093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
6 Vringer M, Kornum BR. Emerging therapeutic targets for narcolepsy. Expert Opin Ther Targets 2021;:1-14. [PMID: 34402358 DOI: 10.1080/14728222.2021.1969361] [Reference Citation Analysis]
7 Poonia N, Lal K, Kumar A. 1,3-Phenylene-based symmetrical bis(urea-1,2,3-triazole) hybrids: Synthesis, antimicrobial and in silico studies as 14α-sterol demethylase inhibitors. Res Chem Intermed. [DOI: 10.1007/s11164-021-04653-x] [Reference Citation Analysis]
8 Waters K. Review of the Efficacy and Safety of Lemborexant, a Dual Receptor Orexin Antagonist (DORA), in the Treatment of Adults With Insomnia Disorder. Ann Pharmacother 2021;:10600280211008492. [PMID: 34078141 DOI: 10.1177/10600280211008492] [Reference Citation Analysis]
9 Suzuki K. Current Update on Clinically Relevant Sleep Issues in Parkinson's Disease: A Narrative Review. J Parkinsons Dis 2021;11:971-92. [PMID: 33896849 DOI: 10.3233/JPD-202425] [Reference Citation Analysis]
10 Sun YY, Wang Z, Zhou HY, Huang HC. Sleep-Wake Disorders in Alzheimer's Disease: A Review. ACS Chem Neurosci 2022. [PMID: 35507669 DOI: 10.1021/acschemneuro.2c00097] [Reference Citation Analysis]
11 Berger B, Muehlan C, Klein G, Dingemanse J. Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment. Clin Transl Sci 2021. [PMID: 34121345 DOI: 10.1111/cts.13079] [Reference Citation Analysis]
12 Boof M, Ufer M, Fietze I, Pépin J, Guern A, Lemoine V, Dingemanse J. Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2021.11.015] [Reference Citation Analysis]
13 Boof ML, Dingemanse J, Lederer K, Fietze I, Ufer M. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 2021;44:zsaa275. [PMID: 33305817 DOI: 10.1093/sleep/zsaa275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chrobok L, Jeczmien-Lazur JS, Bubka M, Pradel K, Klekocinska A, Klich JD, Ridla Rahim A, Myung J, Kepczynski M, Lewandowski MH. Daily coordination of orexinergic gating in the rat superior colliculus-Implications for intrinsic clock activities in the visual system. FASEB J 2021;35:e21930. [PMID: 34533886 DOI: 10.1096/fj.202100779RR] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Schilling U, Henrich A, Muehlan C, Krause A, Dingemanse J, Ufer M. Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis. Clin Drug Investig 2021;41:711-21. [PMID: 34331678 DOI: 10.1007/s40261-021-01062-1] [Reference Citation Analysis]
16 Berger B, Dingemanse J, Sabattini G, Delahaye S, Duthaler U, Muehlan C, Krähenbühl S. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clin Pharmacokinet 2021. [PMID: 34002356 DOI: 10.1007/s40262-021-01028-8] [Reference Citation Analysis]